Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Michael Monsour
Date of last notice	19th October 2017

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	7th February 2018

N	Ondinomy Change
No. of securities held prior to change	Ordinary Shares
	Dr Michael Monsour
	• 2,932,129 Ordinary Shares
	MPAMM Pty Ltd
	• 50,273,758 Ordinary Shares
	MP Monsour Medical Practice Pty Ltd
	<superannuation account=""></superannuation>
	• 265,215,686 Ordinary Shares
	Halonna Pty Ltd < Monsour Family A/C
	• 314,339,667 ordinary shares
	ALTOA – listed options
	• 2,500,000 MP Monsour Medical Practice
	Pty Ltd
	<superannuation account=""></superannuation>
	• 14,166,666 Halonna Pty Ltd < Monsour
	Family A/C
	Unlisted options
	MP Monsour Medical Practice Pty Ltd
	<superannuation account=""></superannuation>
	• 13,000,000 unlisted options expiring 29
	October 2018
	• 20,000,000 unlisted options expiring 22
	December 2021
	Unlisted options expiring Jan 2018  Dr Michael Monsour
	• 325,792
	MPAMM Pty Ltd
	• 5,585,973
	MP Monsour Medical Practice Pty Ltd
	<superannuation account=""></superannuation>
	• 29,468,409
	Halonna Pty Ltd < Monsour Family A/C
	• 34,926,629
	Unlisted options expiring May 2018
	Dr Michael Monsour
	• 325,792
	MPAMM Pty Ltd
	• 5,585,973
	MP Monsour Medical Practice Pty Ltd
	<superannuation account=""></superannuation>
	• 29,468,409
	Halonna Pty Ltd < Monsour Family A/C
	• 34,926,629
Class	Ordinary shares
	Unlisted options
Number acquired/disposed	70,306,803 ordinary shares acquired on
Transport acquired aloposed	conversion of 70,306,803 Options expiring on
	31 January 2018
	5. Sandary 2010

Appendix 3Y Page 2 01/01/2011

Number disposed	-
Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	\$351,534
No. of securities held after change	Ordinary Shares
	Dr Michael Monsour
	3,257,921 Ordinary Shares
	MPAMM Pty Ltd
	• 55,859,731 Ordinary Shares
	MP Monsour Medical Practice Pty Ltd
	<superannuation account=""></superannuation>
	• 294,684,095 Ordinary Shares
	Halonna Pty Ltd < Monsour Family A/C
	• 349,266,296 ordinary shares
	ALTOA – listed options
	2,500,000 MP Monsour Medical Practice
	Pty Ltd
	<superannuation account=""></superannuation>
	• 14,166,666 Halonna Pty Ltd < Monsour
	Family A/C
	Unlisted options
	MP Monsour Medical Practice Pty Ltd
	<superannuation account=""> 13 000 000 unlisted entires expiring 30</superannuation>
	13,000,000 unlisted options expiring 29 October 2018
	• 20,000,000 unlisted options expiring 22
	December 2021
	Unlisted options expiring May 2018
	Dr Michael Monsour
	• 325,792
	MPAMM Pty Ltd
	• 5,585,973
	MP Monsour Medical Practice Pty Ltd
	<superannuation account=""></superannuation>
	• 29,468,409
	Halonna Pty Ltd < Monsour Family A/C
	• 34,926,629
Nature of change	Conversion of unlisted options expiring on 31
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	January 2018

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-

## Appendix 3Y Change of Director's Interest Notice

Name of registered holder (if issued securities)	-
Date of change	-
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	-
Interest acquired	-
Interest disposed	-
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	-
Interest after change	-

## Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a $^+$ closed period where prior written	
clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

Appendix 3Y Page 4 01/01/2011

Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ross Mangelsdorf
Date of last notice	4th December 2017

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Tambien Pty Ltd and Edmonmont (Mr Mangelsdorf is a director, shareholder, trustee)
Date of change	7th February 2018

No. of securities held prior to change	Ordinary Shares
	Ross James Mangelsdorf
	• 244,587 Ordinary Shares
	Ross Mangelsdorf & Jennifer Margaret
	Mangelsdorf
	• 244,587 Ordinary Shares
	Tambien Pty Ltd
	• 44,613,621 Ordinary Shares
	Edmonmont
	• 24,803,142 ordinary shares
	ALTOA
	Ross James Mangelsdorf
	• 2,370 ALTOA
	Ross Mangelsdorf & Jennifer Margaret
	Mangelsdorf
	• 2,370 ALTOA
	Tambien Pty Ltd
	• 2,230,255 ALTOA
	Edmonmont
	• 380,000 ALTOA
	Unlisted options
	• 10,000,000 unlisted options expiring
	date 29 October 2018
	• 10,000,000 unlisted options. Expiry da
	22 December 2021
	• 10,000,000 unlisted options expiring
	November 2022 with an exercise pric
	of \$0.013 (Tambien Pty Ltd)
	Unlisted options expiring Jan 2018
	Ross James Mangelsdorf
	• 27,176
	Ross Mangelsdorf & Jennifer Margaret
	Mangelsdorf
	• 27,176
	Tambien Pty Ltd
	• 6,734,846
	Edmonmont
	• 4,533,684
	Unlisted options expiring May 2018
	Ross James Mangelsdorf
	• 27,176
	Ross Mangelsdorf & Jennifer Margaret
	Mangelsdorf
	• 27,176
	Tambien Pty Ltd
	• 6,734,846 Edmonment
	Edmonmont

• 4,533,684

	T a a.
Class	Ordinary Shares
	Unlisted options
Number acquired	11,255,382 ordinary shares on conversion
	of 11,255,382 options
Number disposed	Lapsing of 67,500 options expiring 31
-	January 2018
Value/Consideration	\$56,277
Note: If consideration is non-cash, provide details and estimated	, , , , , , , , , , , , , , , , , , ,
valuation	
No. of securities held after change	Ordinary Shares
	Ross James Mangelsdorf
	• 271,763 Ordinary Shares
	Ross Mangelsdorf & Jennifer Margaret
	Mangelsdorf
	• 271,763 Ordinary Shares
	Tambien Pty Ltd
	• 51,280,967 Ordinary Shares
	Edmonmont
	• 29,336,826 ordinary shares
	ALTOA
	Ross James Mangelsdorf
	• 2,370 ALTOA
	Ross Mangelsdorf & Jennifer Margaret
	Mangelsdorf
	• 2,370 ALTOA
	Tambien Pty Ltd
	• 2,230,255 ALTOA
	Edmonmont
	• 380,000 ALTOA
	Unlisted options
	• 10,000,000 unlisted options expiring
	date 29 October 2018
	• 10,000,000 unlisted options. Expiry date 22 December 2021
	• 10,000,000 unlisted options expiring 30
	November 2022 with an exercise price
	of \$0.013 (Tambien Pty Ltd)
	Unlisted options expiring May 2018
	Ross James Mangelsdorf
	• 27,176
	Ross Mangelsdorf & Jennifer Margaret
	Mangelsdorf
	• 27,176
	Tambien Pty Ltd
	• 6,734,846
	Edmonmont
	• 4,533,684

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of options expiring on 31 January 2018

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder	-
(if issued securities)	
Date of change	-
No. and class of securities to which	-
interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	-
Interest disposed	-
Value/Consideration	-
Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	-
1	

### Part 3 – +Closed period

Were the interests in the securities or contracts detailed	No
above traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

Rule 3.19A.2

# **Appendix 3Y**

# **Change of Director's Interest Notice**

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ANALYTICA LIMITED
ABN	12 006 464 866

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Peter B. Corr
Date of last notice	4 <sup>th</sup> December 2017

#### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect interest	
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	INOV8 LLC - Dr Corr is director and major shareholder	
Date of change	7th February 2018	
No. of securities held prior to change	INOV8 LLC Ordinary Shares - 360,790,157 Unlisted options expiring Jan 2018 40,087,795 with an exercise price of \$0.005 Unlisted options expiring May 2018 40,087,795 with an exercise price of \$0.005 10,000,000 unlisted options with an exercise price of \$0.013 per option and expiring on 30 November 2022.	
Class	Unlisted options	
Number acquired	-	
Number disposed	Expiry of 40,087,795, unlisted options expiring 31 Jan 2018	

Value/Consideration  Note: If consideration is non-cash, provide details and estimated valuation	Nil
No. of securities held after change	INOV8 LLC Ordinary Shares - 360,790,157 40,087,795 with an exercise price of \$0.005 10,000,000 unlisted options with an exercise price of \$0.013 per option and expiring on 30 November 2022.
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buyback	

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	  - 
Date of change	-
No. and class of securities to which	-
<b>interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	-
Interest disposed	-
Value/Consideration  Note: If consideration is non-cash, provide details and an estimated valuation	-
Interest after change	-

### Part 3 – +Closed period

art 5 – Closed period	
Were the interests in the securities or contracts detailed	No
above traded during a <sup>+</sup> closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a